Sagimet Biosciences gets FDA “Study May Proceed” letter for Phase 3
Sagimet Biosciences (SGMT) says the FDA issued a “Study May Proceed” letter and IND clearance for a Phase 3 trial in acne in adolescent and adult patients.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.